Frovocimab
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody to Subtilisin/Kexin Protein Converting Enzyme Type 9 (PCSK9) that binds to the catalytic domain of PCSK9 and lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia.Frovocimab is used in the study of hypercholesterolemia. Frovocimab is used to study hypercholesterolemia.
Product Specifications
CAS Number
1643672-70-1
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Others
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS1474939-01 0.02 mg (E-Coli)
Recombinant Hahella chejuensis Argininosuccinate synthase (argG)
Sign In for Pricing
View Details MBS1474939-02 0.02 mg (Yeast)
Recombinant Hahella chejuensis Argininosuccinate synthase (argG)
Sign In for Pricing
View Details MBS1474939-03 0.1 mg (E-Coli)
Recombinant Hahella chejuensis Argininosuccinate synthase (argG)
Sign In for Pricing
View Details